氯吡格雷是急性冠狀動(dòng)脈綜合征（ACS）和經(jīng)皮冠狀動(dòng)脈介入術(shù)（PCI）后抗血小板的基礎(chǔ)藥物，其臨床效應(yīng)在不同患者間存在明顯的個(gè)體差異。基因多態(tài)性可以解釋10%～50%氯吡格雷個(gè)體間的差異，而CES1參與了氯吡格雷的主要失活途徑。目前研究報(bào)道的CES1基因多態(tài)性主要是CES1 G143E、CES1A2 A（-816）C和CES1 S75N。主要綜述CES1基因多態(tài)性與氯吡格雷療效個(gè)體差異相關(guān)性的研究進(jìn)展。

Clopidogrel is a primary antiplatelet agent after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). There are significant individual differences in its clinical effect among different patients. Genetic polymorphism can explain between 10% and 50% of the differences in clopidogrel between individuals. CES1 was involved in the main inactivation pathway of clopidogrel. Genetic polymorphisms of CES1 mostly reported were CES1 G143E, CES1A2 A(– 816)C, and CES1 S75N. Research progress on correlation between CES1 gene polymorphisms and the individual differences in the efficacy of clopidogrel is reviewed in this paper.

R968

山東省自然科學(xué)基金資助項(xiàng)目（ZR2018PH044）；山東省醫(yī)藥衛(wèi)生科技發(fā)展計(jì)劃項(xiàng)目（2017WS371）